• Earlier this week, Canaccord Genuity initiated coverage on Pulse Biosciences with a buy rating, highlighting its nanosecond pulsed field ablation platform for cardiac applications and its potential for meaningful commercial adoption.
• In a parallel development, top executives acquired a combined 675,233 shares via the company’s at-the-market equity offering program, underscoring insider confidence in the technology’s commercial prospects.
• Next, we’ll examine how Canaccord Genuity’s backing of Pulse Biosciences’ differentiated cardiac pulsed field ablation platform influences the company’s investment narrative.

Find 47 companies with promising cash flow potential yet trading below their fair value.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you need to believe its nanosecond pulsed field ablation can convert promising thyroid and AF data into real procedure volumes before cash burn forces tough choices. Canaccord Genuity’s new coverage and insider share purchases reinforce interest in the cardiac opportunity, but they do not change the near term catalyst of advancing the NANOPULSE AF IDE study or the core risk of high losses against minimal revenue.

The most relevant recent update here is the European feasibility data for the nPulse Cardiac Catheter System in atrial fibrillation, including 12 month outcomes presented at Heart Rhythm 2026. These results sit at the heart of the story Canaccord is leaning into, because they frame how differentiated the technology looks in a crowded AF market and how much clinical momentum exists ahead of broader commercialization milestones.

Yet against this promising AF data, investors should also weigh the very real risk that procedure adoption and reimbursement progress could lag expectations and...

Pulse Biosciences' narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and a $78.6 million earnings increase from -$74.7 million today.

Uncover how Pulse Biosciences' forecasts yield a $22.00 fair value, a 18% downside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$42.3 million and earnings US$5.7 million by 2029, which is far more bullish than consensus and heavily tied to rapid Vybrance uptake and AF adoption, so you should compare that upbeat view to today’s AF feasibility results and decide how much of that growth story still feels realistic.

Explore 2 other fair value estimates on Pulse Biosciences - why the stock might be worth less than half the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.